~~<i id='E1AB362F19'><strike id='E1AB362F19'><tt id='E1AB362F19'><pre id='E1AB362F19'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

entertainment

author：explore 2025-09-27 13:05:07 - browse：2763

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Philips to halt sales of sleep apnea machines in U.S.

focus

leisure time

focus

explore

CignaisofficiallyexitingtheMedicarebusiness,agreeingtosellallofitsMedicareinsuranceplanstoHealthCare

WSS

Biogen walks away from Aduhelm, years after polarizing approval

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

A disappointing year of Humira biosimilars

Medical mystery: When a cough is not just a cough

How digital tools helped lower hypertension in marginalized patients

Wegovy leads to weight loss. Can it treat depression, too?

Wikipedia

entertainment

focus

BioMarin wins approval for gene therapy to treat hemophilia A

FTC sues over Novant Health acquisition of two N.C. hospitals

Duchenne breakthrough therapy leaves behind pioneering families

Gilead might be held responsible for not developing a drug

How to save PrEP access — and even expand it

Why did Pfizer dish out millions for a Super Bowl ad?

Drug repurposing or repositioning? The language matters

Pancreatic cancer early detection could be helped by AI

In age of alternative facts, a scholarly course on calling out crap

For Medicare Advantage, Democrats want stronger protections around AI

focus

Biogen Alzheimer’s drug launch off to slow start

Reconstructing family trees of blood cells may help predict disease

FTC sues over Novant Health acquisition of two N.C. hospitals

Bernie Sanders is gearing up to subpoena pharma CEOs

For Medicare Advantage, Democrats want stronger protections around AI

How generative AI ratchets up security threats for health systems

leisure time

focus

focus

explore